Novo Nordisk and Eli Lilly vie for reimbursement-driven obesity-drug market as France expands coverageExecutive summary: France's Assurance-maladie started reimbursing Novo Nordisk and Eli Lilly's obesity-treating drugs under specific conditions, effective 15 June 2026. The reimbursement unlocks a large, state-funded market, accelerating commercial rollout and heightening competition for weight-loss drugs in Europe. Novo Nordisk, Eli Lilly, France's Assurance-maladie, European patients with obesity, regulators. Both companies are expected to pursue further reimbursement negotiations across EU health systems, while insurers may tighten cost-effectiveness assessments for obesity therapies.On 15 June 2026 France's Assurance-maladie began reimbursing Novo Nordisk and Eli Lilly's obesity treatments under defined conditions, signalling regulatory acceptance of anti-obesity therapies. The decision creates a sizable, publicly funded market and intensifies competition between the two drugmakers in Europe.Connected developmentsOil prices tumble amid hopes strait of Hormuz will soon reopenEl Ibex amplía sus récords hacia los 19.000 puntosJim Cramer Wasn’t Selling Eli Lilly (LLY)Eli Lilly Stock Hits Buy Zone As Earnings Soar 156%. Funds Are Loading Up.Prediction: Eli Lilly Will Trade at This Price in a YearOpen the full case file on Beyond →
Social Pulse
AI estimate · not scraped